Overcomes endosomal entrapment — a major obstacle to effective intracellular drug delivery
Enables local delivery of functional antisense oligonucleotides (ASOs) and other therapeutic cargos
Achieves rapid delivery into a wide range of cells and tissues, including the skin and lungs — two organs known for their challenging natural barriers that limit traditional delivery methods
With a robust safety profile demonstrated in preclinical studies, the Feldan Shuttle® led to the advancement of our lead candidate, FLD-103, into clinical trials
Unlocking the Full Potential of Antisense Oligonucleotides with the Feldan Shuttle®
Antisense oligonucleotides (ASOs) are a class of RNA therapeutics that selectively silence disease-driving genes. Despite their precision and therapeutic potential, ASOs face a major challenge: they cannot cross cell membranes on their own, limiting their effectiveness. The Feldan Shuttle® addresses this barrier by efficiently delivering ASOs into cells, enabling them to reach their intracellular targets and achieve their intended therapeutic effect.
The Feldan Shuttle® unlocks the therapeutic promise of ASOs and expands their application in novel therapies.
